TOCILIZUMAB
tocilizumab 162 mg/0.9 mL injection, 4 x 0.9 mL syringes
TOCILIZUMAB (12095N)
12095N
Manner of administration:Injection
Restriction
Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient weighing at least 30 kg)
Restriction
Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 2 (retrial or recommencement of treatment after a break
of less than 12 months in a patient weighing at least 30 kg)
Restriction
Indication: Systemic juvenile idiopathic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break of more than
12 months in a patient weighing at least 30 kg)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 4 | # of repeats: 3 | DPMQ: $801.70 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Actemra Subcutaneous Injection | |||||